BioAtla (BCAB) announced data in a poster titled, “Phase 2 Trial of Ozuriftamab Vedotin, a Conditionally Binding CAB-ROR2-ADC, in Patients with ...

Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, today announced promising results from its ...